TOBRAMYCIN SULFATE

Pre-Launch

tobramycin sulfate

ANDAINJECTIONINJECTABLE

Lifecycle

Pre-Launch

Data completeness

2/8 — Basic

TOBRAMYCIN SULFATE (tobramycin sulfate) by Fresenius Kabi is mechanism of action tobramycin acts by inhibiting synthesis of protein in bacterial cells. Approved for serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: septicemia in the neonate, child, uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity.

Drug data last refreshed 1mo ago

Mechanism of Action

Mechanism of Action Tobramycin acts by inhibiting synthesis of protein in bacterial cells. In vitro tests demonstrate that tobramycin is bactericidal.

Indications (3)

serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the neonate child

Worked on TOBRAMYCIN SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.